Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta Bioscience's ROE % for the quarter that ended in Mar. 2026 was 19.07%. Vanta Bioscience's PB Ratio for the quarter that ended in Mar. 2026 was 0.51.
Vanta Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 37.39%.
Vanta Bioscience ROE % Adjusted to Book Value Related Terms
Vanta Bioscience ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience ROE % Adjusted to Book Value Chart
BOM:540729 vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 37.39% mean?
Vanta Bioscience (BOM:540729) has a ROE % Adjusted to Book Value of 37.39% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vanta Bioscience and its competitors.
Is Vanta Bioscience's ROE % Adjusted to Book Value too high?
Vanta Bioscience's current ROE % Adjusted to Book Value is 37.39%. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's ROE % Adjusted to Book Value compare to TMO and DHR?
Vanta Bioscience's ROE % Adjusted to Book Value of 37.39% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current ROE % Adjusted to Book Value is 37.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.97, compared to a current price of ₹25.29 — trading 111.3% above its estimated fair value. The current ROE % Adjusted to Book Value is 37.39%. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current ROE % Adjusted to Book Value is 37.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 111.3% above its estimated GF Value™ of ₹11.97.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
ROE % Adjusted to Book Value: 37.39%
GF Value™: ₹11.97 vs. price of ₹25.29 (111.3% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score
Get the complete analysis for BOM:540729
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
